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Background: We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against
multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further application.
Methods: Six S14161 analogs were designed based on the structure–activity relationship; activity of the
compounds in terms of cell death and inhibition of PI3K were analyzed by flow cytometry and Western blotting,
respectively; anti-myeloma activity in vivo was performed on two independent xenograft models.
Results: Among the six analogs, BENC-511 was one of the most potent compounds which significantly inhibited
PI3K activity and induced MM cell apoptosis. BENC-511 was able to inactivate PI3K and its downstream signals AKT,
mTOR, p70S6K, and 4E-BP1 at 1 μM but had no effects on their total protein expression. Consistent with its effects
on PI3K activity, BENC-511 induced MM cell apoptosis which was evidenced by the cleavage of Caspase-3 and
PARP. Notably, addition of insulin-like growth factor 1 and interleukin-6, two important triggers for PI3K activation in
MM cells, partly blocked BENC-511-induced MM cell death, which further demonstrated that PI3K signaling pathway
was critical for the anti-myeloma activity of BENC-511. Moreover, BENC-511 also showed potent oral activity against
myeloma in vivo. Oral administration of BENC-511 decreased tumor growth up to 80% within 3 weeks in two inde-
pendent MM xenograft models at a dose of 50 mg/kg body weight, but presented minimal toxicity. Suppression of
BENC-511 on MM tumor growth was associated with decreased PI3K/AKT activity and increased cell apoptosis.
Conclusions: Because of its potent anti-MM activity, low toxicity (LD50 oral >1.5 g/kg), and easy synthesis, BENC-511
could be developed as a promising agent for the treatment of MM via suppressing the PI3K/AKT signaling pathway.
Keywords: Phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, BENC-511, S14161, Multiple myeloma, Drug
discoveryIntroduction
The phosphatidylinositol 3-kinases (PI3Ks) are a family
of intracellular lipid enzymes that phosphorylate the 3′-
OH group at the inositol ring of phosphatidylinositol
and convert PI(4,5)P2 to PI(3,4,5)P3 [1,2]. The latter
then acts as a secondary messenger that mediates the
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stated.are responsible for various cell activities, such as tissue
factor expression and coagulation [3], cell proliferation
and survival [4]. Dysregulation of the PI3K/AKT signal-
ing pathway is frequently seen in many cancer types
[5-7], including hematological malignancies, such as
leukemia [8], lymphoma [9], and multiple myeloma (MM)
[10,11]. Overactivation of PI3K/AKT confers chemore
sistance and poor outcomes, while knockdown of PI3K or
AKT leads to cancer cell death [5,12,13]. Therefore, the
PI3K/AKT pathway is regarded as an ideal target for
cancer therapy [5-7]. Actually, more and more PI3K/AKT
inhibitors have been identified, of which some have been
successfully moved into clinical evaluation [14,15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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for more than 10% of all hematological cancers and 2%
of annual cancer-related death [16]. It is believed that
the PI3K/AKT pathway is particularly pertinent for MM
growth and therapy. There are four members in the
Class I PI3K family, namely, PI3Kα, β, δ and γ, all of
which are overactivated in MM cell lines and primary
myeloma patient cells [17]. Moreover, phosphatase and
tensin homolog (PTEN), the critical negative modulator
of PI3K signaling, is frequently deleted or inactivated
by mutation in MM cells [18]. Activation of PI3Ks in
MM is associated with growth factors such as insulin-
like growth factor 1 (IGF-1) and cytokines such as
interleukin-6 (IL-6), both of which are highly expressed
in MM cells [19]. In an analysis of AKT activity in MM
cells, the expression of phosphorylated-AKT (S473) was
found in 16 of 18 patients, which indicates constitutively
phosphorylated-AKT in primary MM cells [20]. In
addition, this key signaling is also an indicator of un-
favorable outcomes of myeloma patients [20]. Moreover,
inhibition of PI3K/AKT leads to MM apoptosis. There-
fore, PI3K/AKT is an ideal target for anti-myeloma drug
discovery. Many inhibitors of the PI3K/AKT signaling
pathway, such as CAL-101, NVP-BKM120, and Perifo-
sine have been developed for MM therapy and are now
evaluated in clinical trials [21-23]. However, there are no
approved PI3K inhibitors available for MM therapy due
to collective efficacy and/or safety issues, novel PI3K in-
hibitors are in demand.
We recently identified S14161 as an inhibitor of pan-
Class I PI3K isoforms by a high throughput screening
strategy [11]. S14161 induces apoptosis in myeloma and
leukemia cell lines as well as primary patient samples.
Notably, S14161 is also effective in leukemia xenograft
models [11]. Given its potent antileukemia and antimye-
loma activity and minimal toxicity, S14161 can serve as
a new lead for cancer drug development. To improve its
physical and chemical properties, such as solubility and
chirality, we designed a series of analogs of S14161 based
on the structure-activity relationship, and identified
BENC-511 as a more potent inhibitor of PI3K signaling
for the treatment of MM.
Results
BENC-511 displays potent inhibitory effects on AKT
activation
We previously reported S14161 as a novel PI3K inhibitor
[11], to improve its physical and chemical properties, we
designed two classes of analogs of S14161. Class I members
WQD-612, DJY-611, DQJ-610 contained the 2-phenyl ring,
but the flouro substituent was replaced with a hydrogen
atom or an electron-withdrawing cyano group or electron-
donating methoxy substituent at the para position
(Figure 1A). Class II members QDF-510 and BENC-511were designed with a simplified structure by removing the
4-fluorophenyl group at the 2-position of the chromene
core (Figure 1A). In the analysis of the effects of these ana-
logs on PI3K activity, we treated the PTEN-negative MM
cell line OPM2 with 4 μM of each compound for 24 hours.
Western blotting analyses revealed that all class I
compounds except DJY-611 showed no significant inhibi-
tory effects on AKT phosphorylation, while the class
II compounds effectively suppressed AKT activation
(Figure 1B). We next evaluated the inhibitory effects of
these compounds on OPM2 cell growth. Over a 72-hour
treatment, BENC-511 was found to be the most potent one
in inhibiting OPM2 cell proliferation by a measurement of
viable cells using MTT assay (Additional file 1: Figure S1).
BENC-511 was then applied for evaluation of AKT phos-
phorylation levels in a panel of MM cell lines, including
RPMI-8226, JJN3, OCI-MY5, U266, LP1, and OPM2. As
shown in Figure 1C, BENC-511 inhibited AKTactivation in
all cell lines examined.
To further characterize the effect of BENC-511 on
AKT activation, BENC-511 was added to RPMI-8226,
LP1, and OPM2 cells from 1 to 4 μM for 24 hours.
Western blotting analysis revealed that AKT phosphor-
ylation was inhibited at both T308 and S473 sites in a
concentration- and time- dependent manner (Figure 1D
and E). Because the full activation of AKT depends on
both T308 and S473 sites, these results suggested that
BENC-511 fully suppressed AKT activation at high
concentrations.
BENC-511 suppresses AKT activation triggered by IGF-1
and IL-6
One of the biological signals that activate PI3K/AKT path-
way is from receptor tyrosine kinases [15]. In MM cells, the
most important signal stimulators are IGF-1 and IL-6
which regulate MM cell growth, proliferation and angio-
genesis [24]. To evaluate the effects of BENC-511 on AKT
activation, 4 MM cell lines RPMI-8226, OPM2, JJN3 and
LP1 were starved overnight and then treated with S14161
(100 μM) or BENC-511 (50 μM) for 2 hours, followed by
stimulation with 100 ng/mL of IGF-1. The phosphorylation
level of AKT at T308 and S473 were measured. It showed
that BENC-511 suppressed AKT activation at both sites in
the presence of IGF-1 (Figure 2A) and BENC-511 seemed
more potent than S14161. As shown in Figure 2A, BENC-
511 almost completely suppressed AKT phosphorylation at
T308 in all cell lines, but there was a certain level of phos-
phorylated AKT remained in cells treated with S14161. To
verify this effect, RPMI-8226 and OPM2 cells were treated
with BENC-511 at 50 or 100 μM for 0.5 to 1 hour, im-
munoblotting assays revealed that 50 μM of BENC-511
suppressed AKT phosphorylation in 0.5 hour (Figure 2B),
while AKT activation was observed after 100 μM of S14161
treatment for 2 hours. Because both cytokine IL-6 and
Figure 1 (See legend on next page.)
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Figure 2 BENC-511 suppresses AKT activation triggered by IGF-1. (A) Myeloma (RPMI-8226, JJN3, LP1 and OPM2) cells were starved
overnight and then treated with 100 μM of S14161, 50 μM of BENC-511, or DMSO for 2 hours, followed by 100 ng/mL of IGF-1 for 15 minutes.
After incubation, cells were harvested and total proteins were isolated. Expression of AKT, p-AKT (T308), p-AKT (S473), and GAPDH was measured
by immunoblotting. (B) RPMI-8226 and OPM2 cells were treated with increasing concentration of BENC-511 for 0.5 or 1 hour, S14161 for 2 hours,
followed by IGF-1 stimulation. Cells were then harvested and total proteins isolated. Expression of AKT, p-AKT (S473), and GAPDH was measured
by immunoblotting. (C) OPM2 cells were starved overnight and then treated with BENC-511 (8 μM), or DMSO for the indicated time followed by
100 ng/mL IGF-1 or 50 ng/mL IL-6 for 15 minutes. After incubation, cells were harvested and total proteins isolated. Expressions of total AKT,
p-AKT (S473), PARP, and GAPDH were measured by immunoblotting. T-AKT: total AKT.
(See figure on previous page.)
Figure 1 BENC-511 displays potent inhibitory effects on AKT activation. (A) The structures of the analogs of S14161, including DQJ-610,
DJY-611, WQD-612, QDF-510, BENC-511. (B) OPM2 cells were treated with 4 μM of S14161, BENC (BENC-511), QDF (QDF-510), DQJ (DQJ-610), DJY
(DJY-611), or WQD (WQD-612) for 24 hours. After incubation, cells were harvested and total proteins were isolated. Expression of p-AKT (S473)
and total AKT were measured by immunoblotting. (C) RPMI-8226 (8226), JJN3, OCI-MY5 (MY5), U266, LP1, OPM2 cells were treated with 4 μM of
BENC-511 or DMSO for 24 hours followed by the analysis of the expression of p-AKT (S473) and total AKT. (D) RPMI-8226, LP1 and OPM2 cells
were treated with increasing concentration of BENC-511 for 24 hours. Expression of p-AKT (S473 and T308), and total AKT were measured by
immunoblotting. (E) RPMI-8226 and OPM2 cells were treated with increasing concentration of BENC-511 for 12 hours followed by the analysis of
AKT activation. GAPDH was used as a loading control. T-AKT: total AKT.
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key regulators of MM cell growth, we next evaluated the ef-
fects of BENC-511 on AKT in the presence of IL-6 and
IGF-1. In this experiment, starved OPM2 cells were treated
with BENC-511 (8 μM) for 0–8 hours, followed by IL-6 or
IGF-1 stimulation. As shown in Figure 2C, BENC-511
suppressed AKT activation raised by both IGF-1 and
IL-6 within 2 or 4 hours. Notably, suppression of AKT
phosphorylation was accompanied by PARP cleavage
(Figure 2C), suggesting AKT suppression by BENC-511
was associated with MM cell apoptosis.
BENC-511 downregulates PI3K/AKT downstream signals
As a central node of various cell signals, PI3K/AKT can
regulate many key important signals, including the mam-
malian target of rapamycin (mTOR), protein 70S6 kinase
(p70S6K), factor 4E binding protein 1 (4E-BP1), and glyco-
gen synthase kinase-3, all of these proteins are key playersFigure 3 BENC-511 downregulates PI3K/AKT downstream signals. OPM
tions of BENC-511 for 24 hours. Whole lysates were subjected to Western b
p70S6K, p-4E-BP1, and 4E-BP1; (C) p-GSK-3β (Ser9). β-actin was used as anin regulating protein synthesis and cell proliferation [25,26].
To evaluate the biological effects of BENC-511 on the
PI3K/AKT signaling pathway, we measured the effects of
BENC-511 on these protein phosphorylation levels. MM
cells were treated with BENC-511 for 24 hours at indicated
concentrations. Immunoblotting assays with specific anti-
bodies demonstrated that BENC-511 inhibited expression
levels of phosphorylated mTOR as well as its adaptor pro-
tein Raptor (Figure 3A), phosphorylated p70S6K and 4E-
BP1 (Figure 3B). BENC-511 also induced GSK-3β activation
as seen in its phosphorylation level (Figure 3C). These
changes, consistent with previous reports on PI3K inhibi-
tors [27], further demonstrated that BENC-511 was an in-
hibitor of PI3K.
BENC-511 induces MM cell apoptosis
Inhibition of PI3K/AKT results in apoptosis of cancer cells.
S14161 has been demonstrated to induce MM cell death by2, RPMI-8226 and LP1 cells were treated with increasing concentra-
lot analysis. (A) p-mTOR (Ser2448), T-mTOR, Raptor; (B) p-p70S6K,
internal control.
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investigate the effects of BENC-511 on MM cell apoptosis,
we first evaluated the effects of BENC-511 on 5 MM cell
lines. BENC-511 cleaved PARP and Caspase-3 (Figure 4A),
and this effect was presented in a concentration- and time-
dependent manner (Figure 4B). BENC-511 induced MM
cell apoptosis at 0.5 μM within 24 hours (Figure 4B). A
time-course study demonstrated that BENC-511 at 8 μM
could cleave PARP within 2 and 4 hours in RPMI-8226 and
OPM2 cells, respectively (Figure 4C).
To further demonstrate cell apoptosis, we measured
cell apoptosis by Annexin-V and propidium iodide stain-
ing, where Annexin V specifically binds to phosphatidyl-
serine on the surface of apoptotic cells while propidium
iodide can penetrate into the dead cells and binds to the
nuclei. Flow cytometric analyses revealed that BENC-
511 at 1 μM induced more apoptotic cells than S14161
at 1 μM. For example, the apoptotic and dead fractions
of LP1 cells was 15.87% and 23.95%, respectively, whenFigure 4 BENC-511 activates apoptotic signaling in MM cells. (A) Mye
4 μM BENC-511 or DMSO for 24 hours followed by the analysis of the expr
cells were treated with increasing concentrations of BENC-511 for 24 hours
the indicated time. After incubation, cells were harvested and total protein
GAPDH analyses.treated with BENC-511, however, these fractions were
only 8.3% and 6.77%, respectively, if treated with S14161
at the same concentration and incubation time (Figure 5).
Therefore, BENC-511 was more potent than S14161 in
cell apoptosis induction.
BENC-511 induces MM cell apoptosis in the presence of
IL-6 or IGF-1
As stated earlier, cytokines such as IL-6 and growth factors
such as IGF-1 are key triggers of the PI3K/AKT signaling
pathway, and critical regulators in MM cell proliferation.
To find out whether BENC-511 inhibits PI3K activity is as-
sociated with its anti-myeloma activity, OPM2 cells were
treated with BENC-511 from 0.5 to 4 μM or S14161
(4 μM) in the presence of IL-6 or IGF-1 for 24 hours.
Apoptotic analyses with PARP suggested that BENC-511
markedly induced PARP cleavage at 1 μM, however,
S14161 generated minimal effects at 4 μM. In the presence
of IL-6 or IGF-1, cell death was partly blocked, especially atloma cells (RPMI-8226, JJN3, OCI-MY5, U266, LP1) were treated with
ession of PARP, Caspase-3, and GAPDH. (B) OPM2, RPMI-8226 and LP1
. (C) OPM2 and RPMI-8226 were incubated with 4 μM of BENC-511 for
s were isolated. Cell lysates were applied for PARP and
DMSO S14161-1 µM BENC-0.5 µMBENC-1 µM
6.38%4.98% 6.77% 23.95%
LP1 
83.84% 6.81% 80.95% 8.3% 79.69% 9.35% 53.71%15.87%
12.51%4.77% 5.77% 10.75%
OCI-MY5
65.84% 11.70%82.21% 6.59% 82.08% 8.40% 68.84% 10.58%
5.56% 6.97% 11.25% 23.71%
OPM2
83.37% 5.32% 77.92% 7.20% 62.93% 15.63% 51.89% 18.00%
5.86% 6.25% 7.21% 22.28%
RPMI-8226
82.58% 6.85% 82.41% 7.18% 78.34% 9.17% 54.58% 16.91%
Annexin V-FITC
Figure 5 BENC-511 induces MM cell apoptosis. LP1, OCI-MY5, OPM2 and RPMI-8226 were treated with 1 μM of S14161, 0.5 or 1 μM of BENC-
511 (BENC) and DMSO for 24 hours. Cells were then stained with Annexin V-FITC and PI and analyzed on a BD FACSCalibur™ flow cytometer.
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strated that BENC-511 induced MM cell apoptosis by tar-
geting the PI3K signaling pathway.
IL-6 and IGF-1 can be secreted by the bone marrow stro-
mal cells (BMSC) and regulate proliferation and survival of
MM cells by regulating the PI3K/AKT signaling pathway
via autocrine and/or paracrine manners [26,28]. To further
demonstrate the effects of IGF-1 and IL-6 on MM cell
growth, MM cell line OPM2 was cultured alone or in the
presence of human stromal cell line HS-5. PARP cleavage
assay revealed that stromal cells conferred resistance toBENC-511 because the presence of stromal cells attenuated
the effects of BENC-511 on PARP cleavage and AKTactiva-
tion in MM cells (Figure 6B). This further demonstrated
that BENC-511 induced MM cell apoptosis in association
with PI3K/AKT signaling.
BENC-511 induces MM cell death in vivo and delays
tumor growth in myeloma xenograft models
To further evaluate the therapeutic effects of BENC-511 in
MM, two myeloma tumor models established with human
MM cell lines OPM2 and RPMI-8226 in nude mice were
Figure 6 BENC-511 induces MM cell apoptosis in the presence of IL-6 or IGF-1. (A) OPM2 cells were co-treated with IL-6, IGF-1 and BENC-
511 with the increasing concentration for 24 hours. After incubation, cells were harvested and cell lysates were measured for the expression of
PARP and GAPDH by Western blotting. (B) MM cell lines OPM2 was co-cultured overnight with human bone marrow stromal cell HS-5, followed
by treatment with BENC-511 overnight. Cells were then collected for PARP, p-AKT (S473) and total AKT (T-AKT) analysis.
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in Figure 7A, BENC-511 at 50 mg/kg/day significantly de-
creased tumor growth within one week in both models.
BENC-511 delayed MM tumor growth in a time-
dependent manner. At the end of the experiment with 20-
day treatment, the average tumor sizes were decreased to
25% and 21.2% compared with the control treated with ve-
hicle in OPM2 and RPMI-8226 models, respectively
(Figure 7A).
To check whether tumor decrease was associated with
PI3K inhibition and apoptosis induced by BENC-511,
tumor tissue extracts were subject to immunoblotting ana-
lyses. The results showed that both PARP and Caspase-3
were markedly cleaved in BENC-511 treated mice
(Figure 7B). To our expectation, AKT phosphorylation wassignificantly suppressed in tumors from BENC-511-treated
mice (Figure 7C). p70S6K and mTOR phosphorylation was
also decreased in the same pattern as AKT (Figure 7D).
However, BENC-511 had no changes in total protein levels
in AKT, p70S6K, or mTOR (Figure 7). These data thus fur-
ther demonstrated that BENC-511 was effective in the
treatment of MM both in vitro and in vivo, which was
highly associated with the suppression of the PI3K/AKT
signaling pathway by BENC-511.
BENC-511 displays minimal toxicity in vivo
Notably, there were no overt toxic changes in gross organs
or body weight (Data not shown) after BENC-511 treat-
ment up to 3 weeks (data not shown). To further evaluate
the toxicity of BENC-511 in vivo, blood samples were taken
Figure 7 BENC-511 induces MM cell death in vivo and delays tumor growth in myeloma xenograft models. Human multiple myeloma
cells (RPMI-8226 and OPM2) were injected subcutaneously into nude mice with a density of 30 million cells/site. When tumors were palpable,
mice (n = 10/group) were orally given BENC-511 (50 mg/Kg body weight) in PBS containing 10% Tween 80 and 10% DMSO daily for continuous
20 days. Tumor volumes (A) were monitored every other day. *, p < 0.05; #, p < 0.01. Tumor samples from each group were subject to immuno-
blotting analysis for PARP, Caspase-3, phospho-AKT, T-AKT, p-mTOR, T-mTOR, p-p70S6K, and p70S6K with specific antibodies (B, C, and D).
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and subject to hematology and biochemical analyses. The
results showed that there were no significant changes in
blood cell and platelet counts, and hemoglobin measure-
ment (Table 1). Further evaluation focused on biochemical
and enzymatic analyses that are associated with liver and
kidney function, including aspartate aminotransferase
(AST), alanine aminotransferase (ALT), blood urea nitrogen(BUN), and creatinine (Cr). Studies were performed based
on 6 mice from each group and it showed that there were
no marked changes in these biomarkers (Table 2).
All these data thus suggest that BENC-511 is not
toxic to liver and kidney. Taken together with the ef-
fects of body weight and blood analyses, BENC-511
was concluded as a non-toxic or minimal toxic
chemical compound.
Table 1 Toxicology of BENC-511 in nude mice: hematology analysis
Treatment WBC (109/L) RBC (1012/L) HGB (g/L) PLT (109/L)
Control 1.81 ± 0.65 7.54 ± 1.37 110.00 ± 18.80 511.92 ± 134.68
BENC-511 1.70 ± 0.50 8.18 ± 1.97 123.80 ± 29.78 530.50 ± 112.82
P 0.89 0.68 0.47 0.58
Data represent mean ± SD of 6 nude in each group. Female nude mice (n = 6 mice per group) were treated with BENC-511 at 50 mg/kg body weight or vehicle
for 20 days. Blood samples were collected in tubes containing EDTA as anticoagulant and subject to hematological analysis. WBC: White blood cell; RBC: Red blood
cell; PLT: Platelets; HGB: haemoglobin.
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The above study demonstrated that BENC-511 was signifi-
cantly improved in terms of its activity to suppress PI3K/
AKT activation, to induce MM cell apoptosis, and to delay
tumor growth in vivo. Because of the minimal toxicity and
great potency in the treatment of MM in vitro and in vivo,
BENC-511 has a great potential for MM treatment.
S14161 has been demonstrated as a pan-PI3K inhibi-
tor, which has no effects on PI3K associated enzymes in-
cluding AKT, mTOR, PDK1 or GSK-3β. Cell-based and
mice-based studies showed that S14161 could be a good
candidate for leukemia and myeloma treatment. How-
ever, the presence of the chiral structural 4-fluorophenyl
group at the chromene brings more work in its prepar-
ation and safety evaluation. Thalidomide, the then-best
drug for morning sick, turned to be a teratogen which
results in thousands of malformed babies due to the less
knowledge in the chiral structure [29-31]. Now it is clear
that in the two enatiomers of thalidomide, the “R” en-
antiomer is a relatively safe drug with sedative attributes,
while the “S” enantiomer has devastating effects such as
teratogenicity [32,33]. Therefore, to improve the efficacy
and to reduce the potential safety issue, we synthesized a
series of analogs of S14161. The enzymatic assay re-
vealed that the phenyl group is not important because
when the whole fluorophenyl group is removed, the re-
sultant QDF-510 and BENC-511 remain active in sup-
pressing PI3K. Therefore, this structural optimization
demonstrated that the 4-fluorophenyl group on chro-
mene is dispensable for this class of PI3K inhibitors.
Beyond our prediction, removal of the phenyl ring in-
creases but not decreases the suppressive activity of S14161
in PI3K inhibition because 4 μM of BENC-511 completelyTable 2 Toxicology of BENC-511 in nude mice: biochemical an
Treatment ALT, U/L AST, U/L
Control 62 (29.3 to 94.7) 237.7 (214.1 to
BENC-511 48.2 (35.3 to 61.1) 189 (170.8 to 2
P 0.6 0.3
Data represent mean ± SD of 6 nude in each group after treatment with BENC-511
periment, mice were sacrificed and their sera were prepared for chemistry analysis.
aminase; AST = Aspartate aminotransferase; BUN = Blood urea nitrogen; Cr = Creatinsuppresses AKT activation within 24 hours, however, it was
not markedly affected by S14161 in the same time frame.
In the short-term treatment, a certain level of AKT phos-
phorylation remains at 100 μM within 2 hours, which is
similar to LY294002, the classic pan-PI3K inhibitor [34,35].
In contrast, BENC-511 almost suppressed AKT phosphor-
ylation at 50 μM within 30 minutes.
Although other residues could be phosphorylated in
AKT, its activation mainly depends on two sites, T308
and S473 [36], and T308 activation is mediated by PI3K
via the phosphatidylinositol 3-kinase-dependent kinase 1
(PDK1) and it leads to activation of mTOR complex 1
(TORC1) in which mTOR activation occurs at S2448.
Our study clearly demonstrated that BENC-511 inhib-
ited AKT activation at T308 which suggests that BENC-
511 probably inhibits PI3K activity. Phosphorylation on
S473 facilitates fully activation of AKT, but BENC-511
can inhibit AKT at both T308 and S473 sites, therefore,
BENC-511 fully inhibits AKT activation.
PI3K/AKT is the center node of a pyramid of cell signal-
ing pathways including mTOR, p70S6K, 4E-BP1, and GSK-
3β signals. mTOR is a serine/threonine protein kinase that
regulates PI3K/AKT signals and is frequently referred to as
the PI3K/AKT/mTOR signaling pathway [37]. Investiga-
tions on PI3K/AKT signaling found that PI3K/AKT inhib-
ition leads to suppressed activation of its downstream
signals mTOR, p70S6K, and 4E-BP1 [15]. BENC-511 has
no inhibitory effects on AKT and mTOR in the cell-free
based enzymatic assays but potently suppresses AKT and
mTOR phosphorylation in cultured cells, suggesting that
BENC-511 inhibits PI3K activation. p70S6K is a kinase that
activates the S6 ribosomal protein thus inducing protein
synthesis [38]. 4E-BP1 is a repressor of protein translationalysis
BUN, mmol/L Cr, μmol/L
261.2) 10.3 (9.0 to 11.5) 10.7 (7.9 to 13.5)
07.2) 11.3 (8.9 to 13.7) 12.4 (11.2 to 13.6)
0.3 0.4
at 50 mg/kg body weight or vehicle for 20 days. At the completion of the ex-
Data represent mean values and 95% confidence intervals. ALT = Alanine trans-
ine.
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Both p70S6K and 4E-BP1 phosphorylation are regulated by
the PI3K/AKT signaling [39,40]. In contrast to p70S6K and
4E-BP1, GSK-3β is negatively regulated by the PI3K/AKT
signaling. The effects of BENC-511 on these signals are
consistent with its effect on PI3K/AKT, which further sug-
gests that BENC-511 inhibits the PI3K signaling pathway.
The PI3K/AKT signaling pathway is important for MM
cell proliferation, survival and anti-apoptosis, downregula-
tion of PI3K activity leads to MM cell death and decreased
proliferation. In agreement with its potent activity on PI3K,
BENC-511 is more effective than S14161 in inducing MM
cell apoptosis. Notably, this apoptosis induced by BENC-
511 could be partly attenuated by PI3K activation upon
treatment with IL-6 or IGF-1, two key factors of PI3K sig-
naling stimulation and key survival factors for MM cells,
which further demonstrates that BENC-511 induces MM
apoptosis by targeting the PI3K signaling pathway. Impres-
sively, the anti-myeloma activity of BENC-511 is also
proven in myeloma xenograft models. More than 75% in-
hibition on MM tumor growth in two different models by
oral administration suggests that BENC-511 is highly effica-
cious. Importantly, activation of PI3K activity indicators
AKT, mTOR, and p70S6K are also significantly decreased
by BENC-511 in myeloma tumor tissues excised from ex-
perimental mice, which was accompanied by Caspase-3 ac-
tivation. Collectively, all these findings demonstrated that
BENC-511 not only induces apoptosis but also delays
tumor growth in MM xenografts, which is associated with
its inhibition on PI3K signals.
In summary, we developed BENC-511 as a more potent
PI3K inhibitor than its parental compound by structural
optimization. Because of its minimal toxicity and high effi-
cacy, BENC-511 could be developed as a potent orally ac-




MM cell lines LP1, OCI-MY5, OPM2, and JJN3 were
kindly provided by Dr. Aaron Schimmer from Ontario
Cancer Institute, Toronto, Canada. RPMI-8226 and U266
were purchased from American Type Culture Collection
(Washington, DC, USA). Human bone marrow stromal cell
line HS-5 was generously provided by Prof. Lin Yang, the
Cyrus Tang Hematology Center, Soochow University. All
cell lines were maintained in Iscove’s modified Dulbecco
medium (Hyclone), supplemented with 10% fetal bovine
serum, 100 μg/ml penicillin, and 100 U/mL streptomycin
(Hyclone Laboratories, Logan, UT).
Preparation of S14161 and its analogs
8-Ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14
161) was synthesized using the domino oxa-Michael-Henry reactions of salicylaldehyde with β-nitrostyrene
[41]. As shown in Figure 1A, WQD-612 had a replace-
ment of the fluoro substituent with a hydrogen atom at
the para position of the 2-phenyl ring in S14161, while
DQJ-610 and DJY-611 had an electron-withdrawing cy-
ano group and electron-donating methoxy substituent at
the same position, respectively. Since S14161 has one
chiral center in its structure and it was used as a racem-
ate in its biological studies, we further simplified its
structure by removing the 4-fluorophenyl group at the
2-position of the chromene core, which generated the 8-
ethoxy-3-nitro-2H-chromene (QDF-510) and 6-bromo
derivative BENC-511 [41].
AKT phosphorylation analysis
Multiple myeloma cell lines were maintained overnight
in Iscove’s modified Dulbecco’s medium containing 0.5%
fetal bovine serum, and treated with 100 μM of S14161
or BENC-511 for 0.5 to 2 hours before stimulation with
100 ng/mL human recombinant insulin-like growth
factor-1(IGF-1, PeproTech, Rocky Hill, NJ) or 50 ng/mL
of interleukin-6 (IL-6, Novoprotein, Summit, NJ) for 15
minutes before being lysed in a RIPA buffer containing
1 mM orthovanadate [11]. After clarification, cell lysates
were subjected to Western blotting analysis with anti-
phospho-AKT (S473) or anti-AKT.
Cell growth and viability
Myeloma cell lines were plated at a density of 1 × 104
cells per well in 96-well plates (Wuxi Nest Biotechnol-
ogy Co., Ltd, Wuxi, China). Cells were treated with
BENC-511 with the increasing concentrations. Cell via-
bility was evaluated by MTT assay as described previ-
ously [42].
Apoptosis assay
PRMI-8226, LP1, OPM2, OCI-MY5 cells were treated with
BENC-511 (0.5, 1 μM) or S14161 (1 μM) for 24 hour using
DMSO as a control. Apoptosis was measured by staining
cells with Annexin V-Fluorescein Isothiocyanate (annexin
V-FITC) and propidium iodide (PI, Sigma) according to the
manufacturers’ instruction. Stained cells were analyzed on a
flow cytometer (FACSCalibur, Becton Dickinson).
Immunoblotting
Whole cell lysates were prepared as described previ-
ously [11]. After proteins were then transferred to
polyvinylidene difluoride membranes, the blots were
then probed with antibodies including monoclonal
PARP, Caspase-3, p-AKT(S473), p-AKT(T308), AKT,
p-mTOR(S2448), Raptor, p-P70S6K, P70S6K, p-4E-
BP1(S65), 4E-BP1 (all were purchased from Cell Sig-
naling Technology, Inc.). GAPDH was purchased
from Abgent. β-actin, anti–mouse immunoglobulin
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conjugated antibody were purchased from R&D
Systems.Multiple myeloma xenograft models
Human multiple myeloma cells (OPM2 and RPMI-
8226) were injected subcutaneously into the right
flanks of nude mice (5–6 weeks old, female, Shanghai
Slac Laboratory Animal Co. Ltd., Shanghai) respect-
ively. When tumors were palpable, mice were ran-
domly divided into two groups (n = 10/group). One
group was given BENC-511 (50 mg/kg body weight)
in PBS containing 10% Tween 80 and 10% DMSO
daily for 20 days, another group was received the ve-
hicle only. Tumor volumes (tumor length × width2 ×
0.5236) were measured over time with a caliper [11].
Mouse body weight was also monitored every other
day. To analyze protein signals from the tumor tis-
sues at the end of the experiment, tumors were ex-
cised and snap-frozen immediately in liquid nitrogen.
Tissue samples were then minced and homogenized
to extract whole cell lysates. The clarified superna-
tants were applied for Western blotting analyses using
specific antibodies.Blood physiochemical assays
At the end of the experiment, whole blood samples
were collected from the eyes and were immediately
subject to complete blood analysis including the white
blood cell (WBC), red blood cell (RBC), platelets
(PLT) and haemoglobin (HGB) measurement on an
automated hematology analyzer (Sysmex KX-21N,
Japan). All samples were analyzed within 30 minutes
after collection. At the same time, blood sera were
isolated by centrifugation at 3,000 × g for 10 minutes
and frozen for further analysis. Liver function was
evaluated with serum levels of physiochemical indexes
including alanine aminotransferase (ALT), aspartate
aminotransferase (AST), blood urea nitrogen (BUN)
and creatinine (Cr). All biochemical assays were per-
formed using a clinical automatic chemistry analyzer
(Suzhou Municipal Hospital, Suzhou, China).Statistical analysis
Data are presented as mean values with 95% confidence in-
tervals (CIs) unless otherwise indicated. For in vivo studies,
the Mann–Whitney rank sum nonparametric method was
used to test for differences between treatment groups in
the weight of the tumors. The t test was used for compari-
sons of two groups in the in vitro studies. All statistical tests
were two-sided, and a P value less than 0.05 was considered
statistically significant.Additional file
Additional file 1: Figure S1. (A) OPM2 cells were treated with
increasing concentration of S14161, BENC-512, DQJ-610, DJY-611,
WQD-612, QDF-511. Seventy-two hours after incubation, cell growth and
viability were measured by the MTT assay. (B) Myeloma (RPMI-8226, JJN3,
LP1, OCI-My5, U266, OPM2) cells were treated with BENC-511 with the
indicated concentration for 72 hours, cell growth and viability were
measured by the MTT assay.
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